This is the text extract for May Tender Notification; Contact: Notifications; Posted: 2012-05-31, browse documents here.

---

31 May 2012

TENDER RESULTS

The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2 November 2010 and 2011/12 Invitation to Tender, dated 1 November 2011 As discussed in our 2010 tender consultation document, we are notifying tender decisions as they are made in 2012. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers. Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website – www.pharmac.govt.nz/schedule.asp. Where a product does not have a current pharmacode, suppliers are required to ensure a pharmacode has been issued by the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct pharmacode.

A512668 - qA21977

Page 1 of 9

---

2011/12 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2015 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

Current subsidy and (price) $315.00 $16.70 $1.28 $3.79 $23.95 $26.49 New subsidy and price $315.00 $13.45 $1.20 $3.48 $15.80 $25.16

The decisions were as follows:

Chemical name Benzathine benzylpenicillin Calamine Chloramphenicol Crotamiton Etidronate disodium Fluorouracil sodium Fluticasone propionate Gentamicin sulphate Hydrocortisone Hydrocortisone Hydroxocobalamin Lithium carbonate

Presentation; Pack size and type Inj 1.2 mega u per 2.3 ml; 10 injections Lotn, BP; 2,000 ml, bottle Eye drops 0.5%; 10 ml OP, bottle dropper Crm 10%; 20 g OP, tube Tab 200 mg; 100 tablets, HDPE bottle Crm 5%; 20 g OP, tube Metered aqueous nasal spray, 50 µg per dose; 120 dose OP, spray bottle Inj 40 mg per ml, 2 ml; 10 ampoules Tab 5 mg; 100 tablets, bottle Tab 20 mg; 100 tablets, bottle Inj 1 mg per ml, 1 ml; 3 ampoules Tab 250 mg; 500 tablets, bottle

Sole supply brand (Supplier) Bicillin L-A (Pfizer) API (API) Chlorafast (Arrow) Itch-Soothe (AFT) Arrow-Etidronate (Arrow) Efudix (Valeant) Flixonase Hayfever & Allergy (GSK) Pfizer (Pfizer) Douglas (Douglas) Douglas (Douglas) ABM Hydroxocobalamin (ABM) Lithicarb FC (Mylan)

Date of subsidy change

Sole Subsidised Supply date

1 July 2012 1 September 2012 1 July 2012 1 July 2012 1 July 2012 1 December 2012

1 October 2012 1 December 2012 1 October 2012 1 October 2012 1 October 2012 1 March 2013

$13.34

$2.30

1 February 2013

1 May 2013

$9.00 $8.35 $20.95 $6.15 $36.10

$6.50 $8.10 $20.32 $5.10 $34.30

1 July 2012 1 September 2012 1 September 2012 1 July 2012 1 July 2012

1 October 2012 1 December 2012 1 December 2012 1 October 2012 1 October 2012

A512668 - qA21977

Page 2 of 9

---

Chemical name

Presentation; Pack size and type Tab 400 mg; 100 tablets, bottle Enema 1 g per 100 ml; 7 bottles Crm 0.1%; 15 g OP tube Crm 0.1%; 45 g OP tube Oint 0.1%; 15 g OP tube Oint 0.1%; 45 g OP tube Tab 10 mg; 50 tablets, blister pack Tab 25 mg; 50 tablets, blister pack Tab 10 mg with hydrochlorothiazide 12.5 mg; 30 tablets, blister pack Tab 20 mg with hydrochlorothiazide 12.5 mg; 30 tablets, blister pack Nebuliser soln, 1 mg per ml, 2.5 ml; 20 dose units Nebuliser soln, 2 mg per ml, 2.5 ml; 20 dose units Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml; 20 dose units

Current subsidy and (price) $13.50 $45.96 $2.38 $4.55 $2.38 $4.55 $2.72 $4.44

New subsidy and price $12.83 $44.12 $1.78 $3.42 $1.78 $3.42 $1.99 $2.99

Sole supply brand (Supplier) Lithicarb FC (Mylan) Pentasa (Pharmaco) m-Mometasone (Multichem) m-Mometasone (Multichem) m-Mometasone (Multichem) m-Mometasone (Multichem) Allersoothe (AFT) Allersoothe (AFT) Accuretic 10 (Pfizer) Accuretic 20 (Pfizer) Asthalin (Rex Medical) Asthalin (Rex Medical) Duolin (Rex Medical)

Date of subsidy change

Sole Subsidised Supply date

Lithium carbonate Mesalazine Mometasone furoate Mometasone furoate Mometasone furoate Mometasone furoate Promethazine hydrochloride Promethazine hydrochloride Quinapril with hydrochlorothiazide Quinapril with hydrochlorothiazide Salbutamol Salbutamol Salbutamol with ipratropium bromide

1 July 2012 1 July 2012 1 July 2012 1 July 2012 1 July 2012 1 July 2012 1 July 2012 1 July 2012

1 October 2012 1 October 2012 1 October 2012 1 October 2012 1 October 2012 1 October 2012 1 October 2012 1 October 2012

$3.37

$3.37

1 June 2012

1 September 2012

$4.57

$4.57

1 June 2012

1 September 2012

$3.52 $3.70

$3.25 $3.44

1 September 2012 1 September 2012

1 December 2012 1 December 2012

$4.29

$3.75

1 September 2012

1 December 2012

A512668 - qA21977

Page 3 of 9

---

2.

Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows: Chemical Name Presentation; Pack size and type Crm aqueous, BP; 100 g tube Cap long-acting 120 mg; 500 capsules, bottle Cap long-acting 180 mg; 500 capsules, bottle Cap long-acting 240 mg; 500 capsules, bottle Tab 200 mg; 60 tablets, bottle Oral liq 5 mg per 5 ml; 100 ml, bottle Current New subsidy subsidy and and price (price) $2.78 $1.77 Sole supply brand (Supplier) Home Essential (API) Date of listing/subsidy change for tender winning brand 1 September 2012 1 December 2012 1 December 2012 1 December 2012 Date of reference pricing of other listed brands 1 November 2012 1 February 2013 1 February 2013 1 February 2013 Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting 1 February 2013 1 May 2013 1 May 2013 1 May 2013 healthE (Jaychem) Cardizem CD (Sanofi) Cardizem CD (Sanofi) Cardizem CD (Sanofi) Viramune (Boehringer Ingelheim) Promethazine Winthrop Elixir (Sanofi)

Calamine Diltiazem hydrochloride* Diltiazem hydrochloride* Diltiazem hydrochloride* Nevirapine**

$4.34 per 30 $31.83 per 500 Apo-Diltiazem CD capsules capsules (Apotex) $6.50 per 30 $47.67 per 500 Apo-Diltiazem CD capsules capsules (Apotex) $8.67 per 30 $63.58 per 500 Apo-Diltiazem CD capsules capsules (Apotex) $319.80 $95.94 Nevirapine Alphapharm (Mylan) Allersoothe (AFT)

1 November 2012

1 January 2013

1 April 2013

Promethazine hydrochloride

$3.10

$2.79

1 November 2012

1 January 2013

1 April 2013

* Brand Switch Fee will be payable for this product from 1 May 2013 until 1 August 2013 subject to implementation of the proposed Pharmacy Services Agreement. ** Brand Switch Fee will be payable for this product from 1 April 2013 until 1 July 2013 subject to implementation of the proposed Pharmacy Services Agreement.

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to pharmaceuticals where no brand is listed.

Presentation; Pack size and type Lotn, BP; 2,000 ml, bottle Crm aqueous, BP; 100 g tube Metered aqueous nasal spray, 50 µg per dose; 120 dose, Hospital Supply Brand (Supplier) API (API) Home Essential (API) Flixonase Hayfever & Allergy DV Limit 1% 1% 1%

The decisions were as follows:

Chemical Name Calamine Calamine Fluticasone propionate

Pack price $13.45 $1.77 $2.30

Listing date 1 September 2012 1 September 2012 1 February 2013

Hospital Supply Status date 1 November 2012 1 November 2012 1 April 2013

A512668 - qA21977

Page 4 of 9

---

Chemical Name

Presentation; Pack size and type spray bottle

Pack price

Hospital Supply Brand (Supplier) (GSK)

DV Limit

Listing date

Hospital Supply Status date

Lithium carbonate Tab 250 mg; 500 tablets, bottle Lithium carbonate Tab 400 mg; 100 tablets,

$34.30 $12.83

Lithicarb FC (Mylan) Lithicarb FC (Mylan)

1% 1%

1 July 2012 1 July 2012

1 September 2012 1 September 2012

4.

Tenders awarded to listed pharmaceuticals where only the current brand is listed.

Chemical Name Benzathine benzylpenicillin Chloramphenicol Crotamiton Dopamine hydrochloride Etidronate disodium Fluorouracil sodium Presentation; Pack size and type Inj 1.2 mega u per 2.3 ml; 10 injections Eye drops 0.5%; 10 ml, bottle dropper Crm 10%; 20 g, tube Inj 40 mg per ml, 5 ml; 10 glass ampoules Tab 200 mg; 100 tablets, bottle Crm 5%; 20 g, tube Inj 40 mg per ml, 2 ml; 10 ampoules Tab 5 mg; 100 tablets, bottle Tab 20 mg; 100 tablets, bottle Current pack price $315.00 $1.28 $3.79 $82.08 $23.95 $26.49 $9.00 $8.35 $20.95 New pack price $315.00 $1.20 $3.48 $69.77 $15.80 $25.16 $6.50 $8.10 $20.32 Hospital Supply Brand (Supplier) Bicillin L-A (Pfizer) Chlorafast (Arrow) Itch-Soothe (AFT) Martindale (Max Health) Arrow-Etidronate (Arrow) Efudix (Valeant) Pfizer (Pfizer) Douglas (Douglas) Douglas (Douglas) DV Limit 1% 1% 1% 1% 1% 1% 1% 1% 1% Date of price change 1 July 2012 1 July 2012 1 July 2012 1 July 2012 1 July 2012 1 December 2012 1 July 2012 1 September 2012 1 September 2012 Hospital Supply Status date 1 September 2012 1 September 2012 1 September 2012 1 September 2012 1 September 2012 1 February 2013 1 September 2012 1 November 2012 1 November 2012

The decisions were as follows:

Gentamicin sulphate Hydrocortisone Hydrocortisone

A512668 - qA21977

Page 5 of 9

---

Chemical Name

Presentation; Pack size and type Inj 1 mg per ml, 1 ml; 3 ampoules Enema 1 g per 100 ml; 7 bottles Crm 0.1%; 15 g tube Crm 0.1%; 45 g tube Oint 0.1%; 15 g tube Oint 0.1%; 45 g tube Tab 10 mg; 50 tablets, blister pack Tab 25 mg; 50 tablets, blister pack Tab 10 mg with hydrochlorothiazide 12.5 mg; 30 tablets, blister pack Tab 20 mg with hydrochlorothiazide 12.5 mg; 30 tablets, blister pack Nebuliser soln, 1 mg per ml, 2.5 ml; 20 dose units Nebuliser soln, 2 mg per ml, 2.5 ml; 20 dose units Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml; 20 dose units

Current pack price $6.15

New pack price $5.10

Hospital Supply Brand (Supplier) ABM Hydroxocobalamin (ABM) Pentasa (Pharmaco) m-Mometasone (Multichem) m-Mometasone (Multichem) m-Mometasone (Multichem) m-Mometasone (Multichem) Allersoothe (AFT) Allersoothe (AFT) Accuretic 10 (Pfizer)

DV Limit 1%

Date of price change

Hospital Supply Status date

Hydroxocobalamin

1 July 2012

1 September 2012

Mesalazine Mometasone furoate Mometasone furoate Mometasone furoate Mometasone furoate Promethazine hydrochloride Promethazine hydrochloride Quinapril with hydrochlorothiazide

$45.96 $2.38 $4.55 $2.38 $4.55 $2.72 $4.44

$44.12 $1.78 $3.42 $1.78 $3.42 $1.99 $2.99

1% 1% 1% 1% 1% 1% 1%

1 July 2012 1 July 2012 1 July 2012 1 July 2012 1 July 2012 1 July 2012 1 July 2012

1 September 2012 1 September 2012 1 September 2012 1 September 2012 1 September 2012 1 September 2012 1 September 2012

$3.37

$3.37

1%

1 June 2012

1 August 2012

Quinapril with hydrochlorothiazide

$4.57

$4.57

Accuretic 20 (Pfizer) Asthalin (Rex Medical) Asthalin (Rex Medical) Duolin (Rex Medical)

1%

1 June 2012

1 August 2012

Salbutamol Salbutamol

$3.52 $3.70

$3.25 $3.44

1% 1%

1 September 2012 1 September 2012

1 November 2012 1 November 2012

Salbutamol with ipratropium bromide

$4.29

$3.75

1%

1 September 2012

1 November 2012

A512668 - qA21977

Page 6 of 9

---

5.

Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

Presentation; Pack size and type Cap long-acting 120 mg; 500 capsules, bottle Cap long-acting 180 mg; 500 capsules, bottle Cap long-acting 240 mg; 500 capsules, bottle Tab 200 mg; 60 tablets, bottle Inj 2 mg per ml, 2 ml; 5 ampoules Inj 2 mg per ml, 4 ml; 5 ampoules Oral liq 5 mg per 5 ml; 100 ml, bottle Inj 10 mg per ml, 5 ml; 10 vials Current pack price New pack Price Hospital Supply Brand (Supplier) DV Limit 5% 5% 5% Date of listing/price change for tender winning brand 1 December 2012 1 December 2012 1 December 2012 Hospital Supply Status date (and delisting of other listed brands) 1 February 2013 1 February 2013 1 February 2013 Brand (Supplier) to be delisted Cardizem CD (Sanofi) Cardizem CD (Sanofi) Cardizem CD (Sanofi) Viramune (Boehringer Ingelheim) Zofran (GSK) Zofran (GSK) Promethazine Winthrop Elixir (Sanofi) Arrow-Rocuronium (Arrow)

The decisions were as follows:

Chemical Name Diltiazem hydrochloride Diltiazem hydrochloride Diltiazem hydrochloride Nevirapine

$4.34 per 30 $31.83 per 500 Apo-Diltiazem CD capsules capsules (Apotex) $6.50 per 30 $47.67 per 500 Apo-Diltiazem CD capsules capsules (Apotex) $8.67 per 30 $63.58 per 500 Apo-Diltiazem CD capsules capsules (Apotex) $319.80 $95.94 Nevirapine Alphapharm (Mylan) Onrex (Rex Medical) Onrex (Rex Medical) Allersoothe (AFT) DBL Rocuronium Bromide (Hospira)

1%

1 November 2012

1 January 2013

Ondansetron Ondansetron Promethazine hydrochloride Rocuronium bromide

$14.40 $23.20

$2.64 $2.98

1% 1%

1 October 2012 1 December 2012

1 December 2012 1 February 2013

$3.10

$2.79

1%

1 November 2012

1 January 2013

$85.00

$38.25

1%

1 July 2012

1 September 2012

A512668 - qA21977

Page 7 of 9

---

2010/11 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2014 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

6. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows: Chemical Name Presentation; Pack size and type Tab 100 mg; 28 tablets, bottle Tab 300 mg with lamivudine 150 mg; 60 tablets, bottle Current New subsidy subsidy and and price price $143.00 $32.50 Sole supply brand (Supplier) Zetlam (Mylan) Alphapharm (Mylan) Date of listing/subsidy change for tender winning brand 1 October 2012 Date of reference pricing of other listed brands 1 December 2012 Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting 1 March 2013 Zeffix (GSK) Combivir (GSK)

Lamivudine* Zidovudine (AZT) with lamivudine*

$667.20

$63.50

1 October 2012

1 December 2012

1 March 2013

* Brand Switch Fee will be payable for this product from 1 March 2013 until 1 June 2013 subject to implementation of the proposed Pharmacy Services Agreement

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

7. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

Presentation; Pack size and type Tab 100 mg; 28 tablets, bottle Tab 300 mg with lamivudine 150 mg; 60 tablets, bottle Current pack price $143.00 $667.20 New pack price $32.50 $63.50 Hospital Supply Brand (Supplier) Zetlam (Mylan) Alphapharm (Mylan) DV Limit 1% 1% Date of listing/price change for tender winning brand 1 October 2012 1 October 2012 Hospital Supply Status date (and delisting of other listed brands) 1 December 2012 1 December 2012 Brand (Supplier) to be delisted Zeffix (GSK) Combivir (GSK)

The decisions were as follows:

Chemical Name

Lamivudine Zidovudine (AZT) with lamivudine

A512668 - qA21977

Page 8 of 9

---

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2009/10 Invitation to Tender, dated 4 December 2009:

Chemical Name Amiodarone hydrochloride Mupirocin Oxybutynin Oxybutynin Inj 50 mg per ml, 3 ml Oint 2% Oral liq 5 mg per 5 ml Tab 5 mg Line Item

For products included in the 2010/11 Invitation to Tender and 2011/12 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Acting Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A512668 - qA21977

Page 9 of 9